Onkologie. 2012:6(6):325-326
Panitumumab in treating patients with advanced metastatic colorectal cancer
- Radioterapeutické a onkologické oddělení, FN a LF UK Plzeň
- Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova v Praze, Plzeň
Panitumumab is the first fully human anti-EGFR monoclonal antibody exhibiting very promising efficacy in patients with the unmutated
(wild) K-ras gene. The therapeutic effect of panitumumab in monotherapy has been presented in crucial phase III trials in which
the time to progression was prolonged significantly in patients treated with panitumumab in monotherapy in comparison with those
who were resistant to standard chemotherapeutic regimens and were receiving supportive therapy. The case report presents a case of
a 70-year-old man with metastatic colorectal cancer in whom long-term partial remission was achieved with panitumumab treatment.
Keywords: colorectal cancer, panitumumab, monotherapy, follow-up
Published: December 1, 2012 Show citation
References
- Schmoll HJ, Büchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol 1999; 26(6): 589-605.
- Goldwasser F. Treatment of metastatic colorectal cancer: an illustration of the changes in the cancer paradigms. Presse Med 2012; 41(1): 46-50.
Go to original source... 
Go to PubMed... - Bartlett DL, Chu E. Can metastatic colorectal cancer be cured? Oncology (Williston Park). 2012; 26(3): 266-275. Go to PubMed...
- Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic Review: Anti-Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer. Ann Intern Med 2011; 154(1): 37-49. Go to original source... Go to PubMed...
- Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25(13): 1658-1664. Go to original source... Go to PubMed...
- Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008; 19(1): 92-98. Go to original source... Go to PubMed...
- Vale CL, Tierney JF, Fisher D, Adams RA, Kaplan R, Maughan TS, Parmar MK, Meade AM. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 2012; 38(6): 618-625. Go to original source... Go to PubMed...
- Elez E, Alsina J, Tanernero J. Panitumumab- an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status. Cancer Treatment Reviews 36S1(2010) S15-S16. Go to original source...
- López-Gómez M, Merino M, Casado E. Long-term treatment of metastatic colorectal cancer with panitumumab. Clin Med Insights Oncol 2012; 6: 125-135. Go to original source... Go to PubMed...